Phase 1 starting soon: SKB107, systemic therapy for bone metastasis

[Maxone73]

The good part is that it's systemic, more precise and designed to target bone metastases only.​

China's National Medical Products Administration (NMPA) has approved the investigational new drug application for SKB107, a first-in-class novel radionuclide-drug conjugate targeting bone metastases in solid tumors.

This therapy combines a small molecule targeting ligand with a therapeutic radionuclide, aiming to deliver precise treatment to metastatic bone lesions while minimizing damage to healthy tissues.

Current treatments offer limited benefits, highlighting the need for innovative approaches like SKB107. The approval marks a significant milestone in addressing this unmet medical need.

AND...let's hope that it will perform in clinical phase as it did in preclinical phase!

prostatewarriors.com/2025/0...

[MikeMartin]

Hey Max hows things? I could not see a link in your article but i did go to: en.kelun-biotech.com/produc.... Implication that a trial might have already started. I though it looks interesting and will follow it as well. Best Mike

[Maxone73 in reply to MikeMartin]

Hey Mike, everything under control for now, I hope you are doing great! I have forgotten the link maybe? I will fix it later. I am not sure that they have already started the clinical trial because they received the approval as investigational drug just few days ago, but I will check! Thanks!